Transfusion News – Thrombosomes (Lyophilized Platelets) Appear Safe in Phase 1 Trial

Data from a phase 1, open-label, multi-center safety trial of lyophilized platelets were recently presented at the 2019 AABB Annual Meeting in San Antonio, Texas. Read More! About Cellphire Cellphire, Inc. is a biotechnology company developing next-generation therapeutics. The company is applying its proprietary cell stabilization technology to all cell types, including platelets, to develop lifesaving products. Its lead product is Thrombosomes®, a freeze-dried hemostatic derived from human platelets. Cellphire’s technology has potential applications across a wide range of medical applications from trauma to wound care, imaging, targeted drug delivery, and regenerative medicine. For more information, visit www.cellphire.com . ‍ Contacts: Media ‍ Sharon Burns Director, Communications [email protected] ‍ Investor Relations Tom Dann Chief Investment Officer [email protected] ‍

The release as fetched from its publisher. cellphire.com ↗